CA2751275A1 - Use of docosahexaenoic acid in treating mild cognitive impairment - Google Patents

Use of docosahexaenoic acid in treating mild cognitive impairment Download PDF

Info

Publication number
CA2751275A1
CA2751275A1 CA2751275A CA2751275A CA2751275A1 CA 2751275 A1 CA2751275 A1 CA 2751275A1 CA 2751275 A CA2751275 A CA 2751275A CA 2751275 A CA2751275 A CA 2751275A CA 2751275 A1 CA2751275 A1 CA 2751275A1
Authority
CA
Canada
Prior art keywords
dha
acid
less
unit dose
per day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2751275A
Other languages
English (en)
French (fr)
Inventor
Karin Yurko-Mauro
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DSM IP Assets BV
Original Assignee
Martek Biosciences Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Martek Biosciences Corp filed Critical Martek Biosciences Corp
Publication of CA2751275A1 publication Critical patent/CA2751275A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
CA2751275A 2009-02-02 2010-02-02 Use of docosahexaenoic acid in treating mild cognitive impairment Abandoned CA2751275A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US14931009P 2009-02-02 2009-02-02
US61/149,310 2009-02-02
US18354809P 2009-06-02 2009-06-02
US61/183,548 2009-06-02
PCT/US2010/022952 WO2010088700A1 (en) 2009-02-02 2010-02-02 Methods for improving cognitive function and decreasing heart rate

Publications (1)

Publication Number Publication Date
CA2751275A1 true CA2751275A1 (en) 2010-08-05

Family

ID=42041547

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2751275A Abandoned CA2751275A1 (en) 2009-02-02 2010-02-02 Use of docosahexaenoic acid in treating mild cognitive impairment

Country Status (8)

Country Link
US (2) US20100203123A1 (OSRAM)
EP (2) EP2939671A1 (OSRAM)
JP (5) JP2012516852A (OSRAM)
CN (3) CN102365087A (OSRAM)
AU (2) AU2016201382A1 (OSRAM)
CA (1) CA2751275A1 (OSRAM)
HK (1) HK1202243A1 (OSRAM)
WO (1) WO2010088700A1 (OSRAM)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8207363B2 (en) 2009-03-19 2012-06-26 Martek Biosciences Corporation Thraustochytrids, fatty acid compositions, and methods of making and uses thereof
US20110177061A1 (en) * 2009-07-10 2011-07-21 Martek Biosciences Corporation Methods of treating and preventing neurological disorders using docosahexaenoic acid
JP2014515928A (ja) * 2011-05-19 2014-07-07 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 認知機能減退に対する医療食品
US8168611B1 (en) 2011-09-29 2012-05-01 Chemo S.A. France Compositions, kits and methods for nutrition supplementation
US20130084272A1 (en) * 2011-09-29 2013-04-04 Philippe Perrin Compositions, kits and methods for nutritional supplementation with twelve carbon chain fatty acids and twelve carbon chain acylglycerols
US9446141B2 (en) * 2013-03-15 2016-09-20 Genspera, Inc. Methods of producing cancer compounds
US9745538B2 (en) 2013-12-20 2017-08-29 MARA Renewables Corporation Methods of recovering oil from microorganisms
TR201503136A2 (tr) * 2015-03-16 2016-09-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dronedaron ve esansiyel yağ asitlerinin farmasötik kompozisyonları.
US10851395B2 (en) 2016-06-10 2020-12-01 MARA Renewables Corporation Method of making lipids with improved cold flow properties
WO2018116093A1 (en) 2016-12-22 2018-06-28 MARA Renewables Corporation Methods for producing biomass rich in dha, palmitic acid and protein using a eukaryotic microorganism
JP7101087B2 (ja) * 2018-09-05 2022-07-14 株式会社 伊藤園 軽度認知障害に対する緑茶成分の有効性評価方法
FR3092968B1 (fr) * 2019-02-22 2021-05-21 Microphyt Complement alimentaire
CN114555074A (zh) * 2019-08-08 2022-05-27 斯威本科技大学 长链多不饱和脂肪酸的用途
WO2021199009A1 (en) 2020-04-03 2021-10-07 MARA Renewables Corporation Microbial oils with high levels of omega-3 fatty acids
DE102020115238A1 (de) * 2020-06-09 2021-12-09 Pm-International Ag Nahrungsergänzungsmittel und Nahrungsmittel
JP7570440B2 (ja) * 2020-07-02 2024-10-21 クリック セラピューティクス インコーポレイテッド デジタル治療プラセボおよびシャムの生成および施用のためのシステム、方法およびデバイス
WO2022152912A1 (en) * 2021-01-15 2022-07-21 Cambridge Cognition Limited Methods and systems of identifying individuals for perioperative neurocognitive disorder and/or post-viral cognitive impairment
WO2024155781A1 (en) * 2023-01-18 2024-07-25 Bioventures, Llc Method of preventing and treating alzheimer's disease and related dementias with drugs inhibiting the interaction between 14-3-3g protein and hexokinase-1 protein
WO2025100476A1 (ja) * 2023-11-10 2025-05-15 国立大学法人京都大学 生理機能改善用の組成物
JP2025079778A (ja) * 2023-11-10 2025-05-22 ダイドーグループホールディングス株式会社 生理機能改善用の組成物

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5407957A (en) 1990-02-13 1995-04-18 Martek Corporation Production of docosahexaenoic acid by dinoflagellates
US20050027004A1 (en) * 1993-06-09 2005-02-03 Martek Biosciences Corporation Methods of treating senile dementia and Alzheimer's diseases using docosahexaenoic acid and arachidonic acid compositions
DE69435246D1 (de) * 1993-06-09 2009-12-03 Martek Biosciences Corp Verwendung von Docosahexaensäure zur Herstellung eines Arzneimittels zur Behandlung der senilen Demenz und Alzheimer-Erkrankung
ATE181745T1 (de) 1994-08-16 1999-07-15 Frische Gmbh Verfahren zur gewinnung von nicht wasserlöslichen, nativen produkten aus nativen stoffgemengen mit hilfe der zentrifugalkraft
DE69637953D1 (de) * 1995-04-17 2009-07-30 Nat Inst Of Advanced Ind Scien Hoch ungesättigte fettsäurenproduzierende mikroorganismen und verfahren zur herstellung von hoch ungesättigten fettsäuren durch verwendung dieser mikroorganismen
JP3985035B2 (ja) * 1995-09-14 2007-10-03 独立行政法人産業技術総合研究所 （ｎ−６）系ドコサペンタエン酸含有油脂ならびに該油脂の製造方法および用途
EP1196518B1 (en) 1999-02-26 2004-08-11 Martek Biosciences Corporation Process for separating a triglyceride comprising a docosahexaenoic acid residue from a mixture of triglycerides
WO2001051598A1 (en) 2000-01-11 2001-07-19 Monsanto Technology Llc Process for making an enriched mixture of polyunsaturated fatty acid esters
ES2735987T3 (es) 2000-01-19 2019-12-23 Dsm Ip Assets Bv Procedimiento de extracción sin disolvente
CN100403917C (zh) 2000-04-12 2008-07-23 威斯特伐利亚分离器股份公司 含油和极性脂质的天然原料的分级分离方法
US20070004678A1 (en) 2001-05-14 2007-01-04 Gerhard Kohn Production and use of a polar lipid-rich fraction containing stearidonic acid and gamma linolenic acid from plant seeds and microbes
CA2451116C (en) 2001-05-14 2013-04-09 Martek Biosciences Corporation Production and use of a polar lipid-rich fraction containing omega-3 and/or omega-6 highly unsaturated fatty acids from microbes, genetically modified plant seeds and marine organisms
WO2003003981A2 (en) * 2001-07-05 2003-01-16 Vital Basics, Inc. Compositions for improving mental performance
EP2921155B1 (en) 2002-05-03 2020-01-08 DSM IP Assets B.V. Methods for producing high-quality lipids by enzymatic liberation from biomass
US8324276B2 (en) * 2005-01-24 2012-12-04 Pronova Biopharma Norge As Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction
JP5503846B2 (ja) * 2005-01-24 2014-05-28 プロノヴァ・バイオファーマ・ノルゲ・アーエス アミロイドーシス関連疾患の治療のための医療品又は食料品の製造における、ｄｈａを含有する脂肪酸組成物の使用
WO2006116755A2 (en) * 2005-04-28 2006-11-02 Trustees Of Tufts College Synergitic effects of docosahexaenoic acid (dha) and carotenoid absorption of cognitive function
WO2006127627A2 (en) * 2005-05-23 2006-11-30 Massachusetts Institute Of Technology Compostions containing pufa and/or uridine and methods of use thereof
CN101262863B (zh) * 2005-07-08 2016-08-31 Dsmip资产公司 用于治疗痴呆和前痴呆相关病症的多不饱和脂肪酸
WO2009002145A1 (en) * 2007-06-26 2008-12-31 N.V. Nutricia Lipid composition for improving function of brain functioning
MX374545B (es) 2007-06-29 2025-03-06 Dsm Ip Assets Bv Produccion y purificacion de esteres de acidos grasos poliinsaturados.
US20110177061A1 (en) * 2009-07-10 2011-07-21 Martek Biosciences Corporation Methods of treating and preventing neurological disorders using docosahexaenoic acid

Also Published As

Publication number Publication date
EP2391361A1 (en) 2011-12-07
EP2939671A1 (en) 2015-11-04
AU2010207929A1 (en) 2011-09-22
US20130172412A1 (en) 2013-07-04
AU2016201382A1 (en) 2016-03-24
US20100203123A1 (en) 2010-08-12
JP2020050675A (ja) 2020-04-02
CN108324706A (zh) 2018-07-27
AU2017245327A1 (en) 2017-11-02
JP2015143248A (ja) 2015-08-06
WO2010088700A1 (en) 2010-08-05
CN102365087A (zh) 2012-02-29
JP2018104477A (ja) 2018-07-05
HK1202243A1 (en) 2015-09-25
JP2022059063A (ja) 2022-04-12
JP2012516852A (ja) 2012-07-26
CN104042600A (zh) 2014-09-17

Similar Documents

Publication Publication Date Title
EP2939671A1 (en) Methods for improving cognitive function and decreasing heart rate
US11413263B2 (en) Reducing the risk of pathological effects of traumatic brain injury
US20100130608A1 (en) Compositions and methods for reducing triglyceride levels
JP6307442B2 (ja) 対象の高感度（ｈｓ−ｃｒｐ）のレベルを低下させる組成物および方法
US20110086914A1 (en) Methods for Treating Traumatic Brain Injury
WO2011097273A1 (en) Methods and compositions for treating non-alcoholic fatty liver disease with docosahexaenoic acid and n-acetyl lcystenine
US20130137767A1 (en) Methods and Compositions for Treating Arthritis with Docosahexaenoic Acid
US20110177061A1 (en) Methods of treating and preventing neurological disorders using docosahexaenoic acid
AU2010207929B2 (en) Methods for improving cognitive function and decreasing heart rate
US20110082205A1 (en) Docosahexaenoic Acid Gel Caps
HK1172241B (en) Reducing the risk of pathological effects of traumatic brain injury
HK1172241A (en) Reducing the risk of pathological effects of traumatic brain injury

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150130

FZDE Discontinued

Effective date: 20190204